In vitro activities of glycoalkaloids from the Solanum lycocarpum against Leishmania infantum

Autor(es)

Clementino, Leandro da Costa ^[1] ; Arenas Velasquez, Angela Maria ^[1] ; Passalacqua, Thais Gaban ^[1] ; de Almeida, Leticia ^[1] ; Graminha, Marcia A. S. ^[2] ; Martins, Gilmarcio Z. ^[3] ; Salgueiro, Ligia ^[4] ; Cavaleiro, Carlos ^[4] ; Sousa, Maria do Ceu ^[4] ; Moreira, Raquel R. D. ^[5]

Afiliação do(s) autor(es)

^[1] Univ Estadual Paulista, UNESP, Inst Quim, Programa Posgrad Biotecnol, Araraquara, SP - Brazil

^[2] Univ Estadual, UNESP, Fac Ciencias Farmaceut, Dept Anal Clin, Araraquara, SP - Brazil

^[3] Ctr Univ Fundacao Educ Barretos, Barretos, SP - Brazil

^[4] Univ Coimbra, Fac Farm, Coimbra - Portugal

^[5] Univ Estadual Paulista, UNESP, Fac Ciencias Farmaceut, Dept Principios Ativos & Nat, Araraquara, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY; v. 28, n. 6, p. 673-677, NOV-DEC 2018.
• Citações Web of Science: 0

Resumo

ABSTRACT Leishmania infantum is an etiologic agent of visceral leishmaniasis. This disease is a neglected disease that can be fatal if not treated and additionally, the few therapeutic option present several drawbacks, including difficult route of administration and toxicity, which turn the search for new therapeutic alternatives necessary. Herein, we evaluated the leishmanicidal in vitro activity of the solanum extract from Solanum lycocarpum A. St.-Hil., Solanaceae, and the isolated alkaloids solasodine, solamargine and solasonine against promastigotes and intracellular amastigotes of L. infantum. Solasodine (IC50-pro = 4.7 µg/ml; IC50-ama = 10.8 µg/ml) and solamargine (IC50-pro = 8.1 µg/ml; IC50-ama = 3.0 µg/ml) exhibited interesting leishmanicidal ativity. Solasonine was approximately four-times (Selective Index 3.7) more selective to the parasite than to the host cells. This data suggest that solasonine might be considered as a potential drug candidate for leishmaniasis treatment. (AU)

• Processo FAPESP: 17/03552-5 - Leishmanioses: do screening ao estudo de mecanismos de ação, uma contribuição para a descoberta de novas moléculas bioativas
• Beneficiário: Marcia Aparecida Silva Graminha
• Modalidade de apoio: Auxílio à Pesquisa - Regular